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Executive Summary
The overall aim of this systems change project is to identify the specific barriers to
optimal care faced by Certified Registered Nurse Anesthetists (CRNAs) who are managing the
pain of opioid tolerant patients, so as to eliminate those barriers.
The postoperative pain of opioid tolerant patients is substantially undertreated, implicitly
requiring changes in their treatment for both ethical and economic reasons. These changes will
require growth in CRNA skills and thinking. Benner’s conceptual framework has been used to
describe this growth in opioid tolerant pain management from novice to expert.
A literature review informed the formulation of a descriptive survey instrument to gather
data on the self-perceived barriers to optimal practice. The questionnaire was distributed via the
American Association of Nurse Anesthetists (AANA) to 2500 practicing CRNAs, achieving a
question response rate of 25.6% (640) to 28.9% (717), yielding a very large sample size for each
question. The survey data were summarized and analyzed to distinguish the several actual from
the numerous possible barriers.
The analyses of the survey results revealed three barriers above all others: (a) a lack of
specific guidelines for opioid tolerant patients, (b) a general failure to use an opioid calculator to
ensure proper dosing, and (c) the very broadly-perceived need for CEUs specifically for
managing the pain of the opioid tolerant patient. To initiate the change process, this study was
presented to members of the Minnesota Association of Nurse Anesthetists. The data and
analysis will serve as a font from which future researchers will draw.
Keywords: Opioid tolerant, Certified Registered Nurse Anesthetist, CRNA, pain
management, preemptive, multimodal

Running head: OPIOID TOLERANT

2

Chapter One: Introduction
This system change project lays a foundation of information intended ultimately to help
Certified Registered Nurse Anesthetists (CRNAs) and other anesthesia providers reduce
perioperative pain for their opioid tolerant patients. The information was acquired via surveying
a random sample of 2500 CRNAs to identify self-perceived barriers to optimal perioperative
pain management for the opioid tolerant. The problem of opioid tolerant pain and its
management has yielded many studies from the perspectives of nursing and anesthesiology, but
to date none have looked at this problem from a CRNA perspective. Identifying which barriers
CRNAs consider most common and significant will help in formulating systemic changes that
will mitigate such barriers and thereby yield better outcomes for this unique patient population.
Significance of the Problem

Despite significant efforts, postoperative pain remains common—up to 70% of
postoperative patients complain of moderate or severe pain (Pyati & Gan, 2007)—and undertreated (Brennan, Carr, & Cousins, 2007). Apfelbaum, Chen, Mehta, and Gan (2003, p. 537)
noted that 73% of hospitalized surgery patients surveyed reported pre-discharge pain, with 88%
of those reporting moderate to extreme pain. Because trauma to the body during surgery may be
very great, the resultant postoperative pain can be severe. Other painful stimuli such as disease,
injury, and inflammation can add to the suffering of a patient who is often in a very vulnerable
state.
Concretely, the anesthesia provider is often a CRNA, and the primary means of
alleviating pain is opioid medication. Despite the many difficulties involved, as Brennan et al.
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(2007) noted, the anesthesia provider has a duty to provide pain relief: “pain management is
required within the highest professional standards” (p. 214).
Opioids at the proper dosage typically relieve pain remarkably well. Unfortunately the
optimum dosage varies widely due to differences not only in inherent pain levels but also to
opioid tolerance and opioid-induced hyperalgesia, which results from prior opioid exposure. If
the need for pain relief imposes a minimum opioid dosage, side effects and over-dosage impose a
maximum risk—even while each of these levels commonly varies dramatically from patient to
patient.

Healthcare economics of suboptimal pain management.
While economics is not always a central concern from an individual patient or clinician
perspective, it is highly significant from a social perspective. In the contexts of costminimization and cost-effectiveness, management of pain in opioid tolerant patients presents a
challenge to health care professionals (Asche, Seal, Jackson, & Oderda, 2006). As a result of
undertreated pain, the time spent in the recovery room and in the hospital is significantly
increased (Dunwoody, Krenzischek, Pasero, Rathmell, & Polomano, 2008), further increasing
the cost. Moreover, it is well documented that other complications resulting from undermanaged
pain include myocardial ischemia and myocardial infarction (Dunwoody et al, 2008), and
increase the heart rate, blood pressure, and oxygen consumption (Spacek, 2006; Lewis, Whipple,
Michael, & Quebberman, 1994). Furthermore, a retrospective study conducted by Coley,
Williams, DaPos, Chen, and Smith (2002), documented undermanaged pain as a major reason
for readmission of patients thereby increasing costs (Coley et al., 2002). Undermanaged pain
also results in lower patient satisfaction (Koo, 2007), further impacting the economics.
Therefore, it is imperative to manage pain optimally to benefit both the patient and the economy.
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Statement of the Problem.
Pain is complex, pain management even more so, and pain management for opioid
tolerant patients perhaps most of all. In so difficult a challenge, every significant barrier to
optimal care must be discovered and removed. This systems change project queries a large
random sample of CRNAs to identify barriers to optimal pain management for opioid tolerant
patients, which is the first critical step to removing them.
Background
Anesthesia care for patients is commonly provided by a CRNA. While it is generally
acknowledged that nurse anesthetists were practicing as early as the mid-to-late 19th century,
formally credentialed CRNAs first appeared in 1945. Today, according to the American
Association of Nurse Anesthetists (AANA), CRNAs safely and effectively administer anesthesia
to approximately 32 million people every year in the United States (AANA, 2011). CRNAs are
the primary anesthesia providers in many rural settings for obstetrical, trauma, and surgical
procedures. In urban and suburban settings, CRNAs more often provide anesthesia in
collaboration with anesthesiologists.
CRNA education.
As noted by the AANA (2011), prospective CRNAs must be licensed registered nurses
with a minimum of a bachelor’s of science in nursing (BSN) or other sufficient baccalaureate
degree and at least one year of acute care experience. CRNA education proper requires a degree
(e.g., Master’s of Nurse Anesthesia) from an accredited graduate school, typically taking 24-36
months, combined with university- or community-hospital-based clinical training. The total
required education is approximately 7 years. The average student nurse anesthetist works for at
least 2,500 clinical hours while handling 850 anesthetic cases. Approximately 2000 students
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graduate each year. CRNAs are required to maintain their certification status by completing a
minimum 40 continuing education credits every two years (Foster & Faut-Callahan, 2001).
The most advanced training recognized is the doctor of nursing practice degree (DNP)
(American Association of Colleges of Nursing [AACN], 2006; Hawkins & Nezat, 2009). This
degree adds a combination of health policy and healthcare economics knowledge, organizational
leadership and management expertise, inter-professional collaboration skills, and quality
improvement and systems change process abilities. The AACN (2006) recommends requiring
this degree for new CRNAs by 2015, while the AANA (2007) supports 2025 as the deadline.
The environment and culture of CRNAs.
The ability of CRNAs to adequately manage pain is dependent in part on the environment
in which they work. This environment presents itself as a complex practice setting due to
various interactions that occur between CRNAs themselves, patients, physicians, and other staff.
Moreover, the decisions made to alleviate pain are not determined by a single consideration, and
often occur in a multidisciplinary approach.
CRNAs’ role in pain management.
From training and experience, CRNAs possess the knowledge, skills, and techniques to
deliver therapeutic pharmacological intervention in the management of both acute and chronic
pain. CRNAs are critical personnel in providing adequate treatment to alleviate pain in
collaboration with other members of a multidisciplinary team (Stomberg, Sjostrom & Haljamae,
2003). The CRNA’s understanding of opioid tolerance is necessary for optimal pain
management, as they are often the in-room providers for perioperative pain management. The
AANA (2010) has published a scope and standards document for nurses' anesthesia practice
consisting of eleven standards, three of which are particularly relevant to opioid tolerant patients
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and thus this thesis. The first AANA standard calls for accurate pre-anesthesia assessment—this
is essential for understanding patients' history of opioid usage. The third standard requires
CRNAs to formulate patient-specific anesthesia plans—for the opioid tolerant patient, this
requires incorporating the patient’s opioid history and calculating doses according. Finally, the
eleventh standard requires that the human rights of all patients be respected, which is important
to remember since opioid tolerant patients may include those addicted to illegal drugs and
commonly seen as undesirable members of society.
Advocacy and ethics.
In general, advocacy refers to extending unconditional support to the well being of the
patient (Benner, 1999). Advocacy is a fundamental aspect of the nursing profession and is often
discussed in nursing literature (American Nurses Association, 2001; Courtenay & Carey, 2008;
Gadow, 1980; Vaartio & Leino-Kilpi, 2005). All ethical codes for CRNAs recommend
advocacy as a core responsibility. In all they do, CRNAs must be patient advocates—this
morality drives every action a CRNA takes. Advocacy requires extending active support to
patients’ rights and choices, helping patients by clarifying medical decisions, and facilitating the
interests of patients, all while providing autonomy and honoring privacy (Hamric, 2000). As the
focus on advocacy indicates, close attention to ethics is fundamental for CRNA delivery of high
quality anesthesia.
Challenges.
Tolerance as a CRNA challenge.
Tolerance to opioids naturally develops in most opioid users, whether chronic pain
patients or illicit consumers, after long-term use. The illicit user is often addicted, while the
great majority of licit users are not (Manchikanti, Cash, Damron, Manchukonda, Pampti, &
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McManus, 2006). However, in each case they are opioid tolerant thereby making management
of their pain complex and challenging. This thesis focuses on opioid tolerant patients regardless
of the nature of the use and irrespective of the presence or absence of addiction. Understanding
the differences between tolerance, dependence, and addiction is important. Basically tolerance is
a physiological adaptation requiring more opioids for the same effect (and, implicitly, delivering
a lesser effect—thus, inadequate analgesia—for the same dosage) (Mitra & Sinatra, 2004).
Dependence is commonly understood as a physical state in which suspension of opioid
consumption results in withdrawal symptoms, while addiction is a psychological condition
involving drug craving and potentially abuse (Mehta & Langford, 2006, pp. 269-270; Morgan &
Christie, 2011, p. 1322). There is overlap between the three concepts, but they are importantly
distinct.
Rapp, Ready, and Nessly (1995) and more recently Patanwala, Jarzyna, Miller, and
Erstad (2008) quantify what opioid tolerance implies for pain management. Rapp et al (1995), in
a case-controlled case review of 360 patients, reported a mean of 3 times the consumption
(morphine equivalent) of patient-controlled anesthesia (PCA) within 24 hours after surgery (p.
198). Patanwala et al. (2008) in their prospective, observational study of 29 total knee
arthroplasty patients, found a PCA multiple of 7. In both studies the patients with a history of
opioid use also had significantly higher pain scores despite the increased PCA, possibly
indicating hyperalgesia. While these multiples cannot be generalized to dissimilar cases
and only a thorough patient history can suggest the optimal dosing in any particular case, these
studies do empirically confirm that a prior history of opioid use will dramatically increase opioid
requirements.
Mechanisms of tolerance.
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Generally, upon initial administration of opioids, analgesia occurs but may be
accompanied by sedation, vomiting, nausea, pupillary constriction, euphoria, or dysphoria. After
repeated administration, the body begins to selectively develop tolerance for these different
effects at different rates (Collett, 1998). For example, tolerance to nausea occurs rapidly while
tolerance to constipation occurs relatively slowly, if at all. Different opioid agonist through
receptor desensitization cause opioid tolerance (Bailey et al., 2009).
Opioids have a long history as analgesics, continuing to this day, almost alone being
capable of relieving the extreme pain in a perioperative setting (Morgan & Christie, 2011).
There are many opioid drugs available, some of which are derived from the opium poppy (the
opiates, e.g., morphine and codeine) and some synthetic (e.g., fentanyl and sufentanil). They
operate on the various opioid receptors of the central nervous system including the mu, delta, and
kappa receptors. These receptors consist of seven transmembrane domains that interact with G
proteins to transmit signals downstream of the opioid agonist binding (Laugwitz, Offermanns,
Spicher &Schultz, 1993). The resultant signals cause analgesia and other effects of opioid
binding including respiratory depression and euphoria (Traynor, 2012). It is common knowledge
that an overdose of opioids will result in increased side effects with no analgesic benefit, while
too small a dose will result in undermanaged pain.
Because the analgesic effect is caused by the binding of chemical receptors (primarily the
mu receptor), the dose response curve assumes a steep sigmoid shape. This is a common
response curve for many drugs and is depicted in Figure 1.
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Figure 1.. Dose versus analgesic response to opioid medication.

The graph illustrates a useful opioid dose response model based on the Fermi equation for the
opioid dose-response
response curve (Peleg, Normand, & Damrau, 1997). ((This
This same approach was also
adopted in generating both the tolerance graph and the tolerance
tolerance-hyperalgesia
hyperalgesia plots.)
plots. The curve
represents the single-dose
dose response to an opioid. The response in the y axis is pain relief for the
patient and, although difficult to reliably quantify, represents a very significant effect for the
patient at optimal dosing. Noteworthy is the narrow dose window caused by the steepness of the
response curve: too-low doses
es are almost completely ineffective, and doses above the ideal
provide little or no benefit (since the receptors are already saturated)
saturated), but increase the side
effects. The phenomenon of tolerance may be pharmacologically modeled by a family of curves,
requiring
uiring larger doses (that is, the curves shifting to the right) as tolerance increases (Figure
(
2).
Figure 3 illustrates the tolerance effect of requiring larger doses while having less pain relief
(lower maximum response).
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Response [Arbitrary]

Tolerance

Increasing
Tolerance

Dose [nM]

Figure 2. The dose needed for a given response increases with tolerance.

Response [Arbitrary]

Simultaneous Tolerance
and Hyperalgesia
Increasing
Tolerance and
Hyperalgesia

Dose [nM]

Figure 3. Hyperalgesia shifts the curve similarly to tolerance but also, by increasing pain
sensitivity, implicitly reduces the maximum opioid analgesic response, sometimes
resulting in the failure of opioid analgesia to control all pain, practically requiring a
multimodal response.

In describing these effects physiologically it is important to note, as Farquhar-Smith
(2007, p. 3) explained, that
Nociceptive energy is transduced into electrophysiological signals that are
transmitted to [the] perceptive apparatus. However, the pain pathway is not
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“hard wired”, but undergoes profound functional changes and modulation
under certain conditions, such as tissue damage and inflammation (e.g.,
postoperative pain).
Opioid-induced tolerance and hyperalgesia are pharmacodynamic examples of pain pathway
modifications (Farquhar-Smith, 2007).
Opioid hyperalgesia.
Another complicating factor caused by changes in opioid receptors is hyperalgesia.
High-dose opioid regimens may cause a paradoxical increase in pain sensitivity. This requires
higher doses for relief, ironically resulting in more hyperalgesia, requiring still more opioids for
relief—an upward spiral of dose escalation. It may be necessary to reduce or even eliminate the
opioid to reverse hyperalgesia (Silverman, 2009, p. 680). Pain may be poorly controlled during
this process, despite large opioid doses, creating difficulties (barriers) for CRNAs managing
these patients.
One way to circumvent the further progression of opioid tolerance is to engage different
receptors and nerve pathways, such as multi-modal drug treatment and adjuvants which can
reduce opioid use and thus their side effects as proposed by DuPen, Shen, and Ersek (2007) in
their comprehensive review of tolerance and hyperalgesia mechanisms.
Pain guidelines.
The most relevant guidelines for perioperative pain management of opioid tolerant
patients come from the American Society of Anesthesiologists (ASA), yet, neither practice
guideline, acute (2004) nor chronic (2010), focuses on the opioid tolerant patient in a
perioperative context. While the chronic guidelines implicitly deal with a partially opioidtolerant population (since many chronic pain suffers are prescribed opioids and many others rely
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on NSAIDs or acetaminophen), the opioid tolerant patient and chronic pain suffering populations
only partially overlap, so guidelines for chronic pain sufferers cannot presumptively be taken as
guidelines for the opioid tolerant.
Purpose of the Study
The main goal of this study was to provide an accurate description of the perception of
pain management practices among CRNAs and to understand various barriers that prevent the
delivery of appropriate pain management to opioid tolerant patients. This systems change
project creates a foundation for both practical changes and future research.
The project objective was to answer the following questions:
1. How do CRNAs manage patients with a history of opioid tolerance presenting for
surgery?
2. What do CRNAs identify as barriers when managing the opioid tolerant patient?

Limitations of the Study

1. The study is limited to CRNAs practicing in the United States and therefore it cannot
be generalized to all CRNAs.
2. This is a descriptive study; inferential analysis was not conducted.
3. The highly subjective nature of the survey and the questionnaire.
4. Day to day variations that are beyond the control of the researcher.
5. Participant bias due the pressure of the obligation to respond in a socially acceptable
manner.
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Assumptions

1. That the participants responded honestly and to the best of their knowledge to the
study survey.
2. That the responses on the survey instrument accurately reflect the CRNA
respondents’ practices of pain management for opioid tolerant patients.
3. That the CRNAs completing the questionnaire will have thorough understanding of
the questions being asked and also have previous experience with the phenomenon of
interest.

Timeframe
This project was conducted from October 2010 through December 2011.
Definitions of Terms
1.

CRNA: a Certified Registered Nurse Anesthetist, that is, an advanced practice registered
nurse specializing in anesthesia.

2.

Pain Management: provision of care that reduces or eliminates pain in patients in
perioperative settings

3.

Opioids: a group of chemical substances that cause morphine-like stimulation in the body.
Opioids function by binding to opioid receptors, resulting in activation of a series of neurochemical pathways. Opioid receptors are distributed widely in the neuronal system.
Opioids can be classified into natural opioids, morphine derivatives semi-synthetic opioids,
fully synthetic opioids, and endogenous opioids (Barash, 1993).

4.

Opioid-Induced Hyperalgesia: a clinical condition under which increase in pain occurs in
patients after receiving repeated doses of opioids. This requires higher doses for relief,
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ironically resulting in more hyperalgesia, requiring still more for relief—an upward spiral of
pain and dose escalation.
5.

Tolerance: an adaptation state wherein drug exposure results in a decrease in the effect of
the drug as a function of time and dose. Tolerance in isolation is not necessarily a sign of
addiction (Mitra & Sinatra, 2004).

6.

Addiction: a maladaptive state in which a person craves and has impaired control over
compulsive drug use, despite harmful results (Collett, 1998).

7.

Multimodal analgesia: an approach during pain management that combines various drugs
(opioid and non-opioid analgesics, local anesthetics) and delivery techniques (e.g.
intravenous anesthesia, patient-controlled anesthesia, regional blockade, and epidural) and is
currently identified as a best practice in pain management (Dahl & Raeder, 2000).

8.

Preemptive analgesia: analgesic treatment started before the induction of noxious stimuli.
This approach reduces both the perioperative pain and reduces the frequency of postoperative pain (Grape & Tramer, 2007).

9.

Post-Operative: perioperative but after the relevant surgery (i.e., excluding an extended time
period).

Summary
This chapter provided a comprehensive background for this study of CRNAs’ selfperceptions of pain management of opioid tolerant patients in order to identify major barriers
pertaining to such. Controlling pain in this group of patients is highly complex due to the
analgesia-nullifying effects of tolerance (and sometimes concomitant hyperalgesia). Due to the
multiple concerns regarding side effects of opioid treatment (including respiratory depression,
nausea, vomiting, and constipation), opioid-sparing modalities must play a major role in
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analgesia with opioid-tolerant patients. Non-pharmacodynamic impediments include the lack of
appropriate guidelines and the variations in the practice environment. A literature review
(following) supports the significance of this study, detailing some of the possible barriers to
optimal care, raising questions which this study helps to answer empirically to the end of optimal
pain relief for opioid tolerant patients.
Forecast
Chapter one provided an overview of the project. The second chapter focuses on offering
a theoretical framework based on Benner (1984, 2001) as it parallels the practice of the nurse
anesthetist and the ethics of nursing, particularly as pertains to the responsibilities of CRNAs in
pain management of opioid tolerant patients. This chapter also includes a comprehensive
literature review and notes the relevant scholarly works that help CRNAs understand pain
processes, opioid tolerance, and opioid-induced hyperalgesia. Chapter 3 explains the
methodology used in this systems change project while Chapter 4 presents the results of this
thesis’s survey of CRNAs from across the United States. The final Chapter 5 puts the findings
from the study in perspective, discussing conclusions and identifying recommendations for
potential future studies.
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Chapter Two: Theoretical Framework and Literature Review
The theoretical framework of this system change project was chosen with the assumption
that there exists substantial and unnecessary pain perioperatively in the opioid tolerant patient,
and expert CRNAs are required to address this important practice problem. The validity of this
assumption is explored via the literature with a view to finding probable causes for this failure of
the medical system. These systems failures are commonly called “barriers” to adequate pain
relief (Coker, Papaioannou, Kaasalainen, Dolovich, Turpie, & Taniguchi, 2010). This study will
focus upon these barriers to ideal analgesic practice which are under the control of the CRNA
and may be practically addressed in the clinical setting.
Underlying this work is another assumption: that there exists an optimal dose of opioids
(combined with adjuvants and other opioid-sparing approaches) which balances pain relief and
negative side effects, both of which are assumed to increase with concentration of opioids in the
blood. CRNAs estimate and administer these doses relying upon their skill and experience,
which thus assume conceptual relevance to this thesis. Barriers to the calculation and
administration of this dose and succeeding doses are targeted for study via the questionnaire
section of this study, which will provide data for the analysis of barriers and permit solutions to
be deduced.
Theoretical Framework
The removal of barriers to good practice requires a growth process. This process can be
conceptualized as a development from lesser to greater competence. As knowledge of barriers is
internalized by the CRNA, a holistic view of the problem will develop through stages of growth
(Jackson, Clements, Averill, & Zimbro, 2009)
Benner (1984) has taught that nurses’ skills go through five distinct stages of
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development: (1) novice, (2) advanced beginner, (3) competent, (4) proficient, and ultimately
(5) expert (1984). As nurses’ experience and education increases, the ability to handle complex
clinical situations (such as opioid tolerance) also increases. These stages are significant enough
to warrant additional detail.
Novice.
Since beginners lack experience, they must rely on scripted roles and rules to perform
their duties. Benner (1984, p. 23) noted:
The rule-governed behavior typical of the novice is extremely limited and
inflexible. The heart of the difficulty lies in the fact that since novices have
no experience of the situation they face, they must be given rules to guide
their performance. But following rules legislates against performance
because the rules cannot tell them the most relevant tasks to perform in an
actual situation.
Advanced beginner.
Those at the advanced beginner level of proficiency have some experience and can
handle many real world situations. Therefore, “[t]he advanced beginner or that person’s
instructor can now formulate principles that dictate actions in terms of both attributes and
aspects” (Benner, 1984, p. 23).
Competent.
Competent nurses in general have several years of practical experience. They are
characterized by the ability to formulate long range goals and the plans to achieve them. Benner
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(1984) noted, “Hence, for the competent nurse, a plan establishes a perspective, and the plan is
based on a considerable conscious, abstract, analytic contemplation of the problem” (p. 26).
Proficient.
As holistic perception develops, unconscious heuristics govern problem solving at this
level of development. Problem solving becomes less self-conscious and more self-evident.
Benner provides the following analysis: “[c]haracteristically, the proficient performer perceives
situations as wholes rather than in terms of aspects, and performance is guided by maxims”
(Benner, 1984, p. 27).
Expert.
Expert performance transcends analysis and rule-following. Problems and solutions are
experienced as gestalts. Benner (1984) stated that, “[e]xpert clinicians are not difficult to
recognize because they frequently make clinical judgments or manage complex clinical
situations in a truly remarkable way” (p. 34).
Furthermore, Benner’s theory illuminates the process by which CRNAs undergo
transformation of personal growth through experience and education. Benner’s work spotlights
the conceptual guideposts which mark the way along the path from novice to expert. On one end
of the spectrum is the novice, who lacks the experience in caring for the opioid tolerant patent.
On the far end of the spectrum is the expert who is able to gestalt the situation and integrate
scientific knowledge and experience to better serve the patient.
Review of the Literature
The literature review focuses broadly on three areas of content. First is the primary
causes of pain, classifying pain according to mechanisms of neural stimulation, elucidating
normal pain pathways, and explaining how these pathways become dysfunctional in opioid
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tolerant patients. Second, current pain relief pharmacology is reviewed, including multimodal
and preemptive analgesia as sophisticated means of managing pain particularly in relation to the
opioid tolerant patient. Finally, it highlights the barriers related to tolerance, hyperalgesia, and
the medical-legal milieu.
The literature review was conducted using Internet search engines, including PubMed,
CINAHL, EBSCO, Medline, and Google Scholar; academic reference lists and textbooks; and
librarians, colleagues, and advisors who provided key input and greater research depth than
would otherwise be possible.
The nature of pain.
Pain plays an essential role in human and animal survival: it protects the organism by
discouraging harmful behavior. Those people who have rare conditions making them incapable
of feeling injury-related pain (e.g., those suffering from leprosy) often inflict grievous harm upon
themselves unknowingly. Pain acts upon the nervous system with high priority. It gets our
attention directly, not allowing us to slowly analyze the situation. Analogous to a computer
interrupt which stops all other action until it is handled, pain ensures that harmful events are
promptly engaged. Furthermore, painful lessons are remembered with intense emotion: “once
bitten, twice shy.”
But occasionally, pain is dysfunctional—most obviously perioperatively. Pain often
serves no purpose here because responsibility for the prevention of bodily harm then resides with
the clinical staff, though even there, pain is sometimes a useful indicator for the clinician of
previously unknown issues. Preventing pain becomes an urgent and critically important but still
routine clinical duty. In this context, the idea that pain is somehow “good for you” is completely
outmoded and anachronistic.
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Surgery without analgesia would be extraordinarily painful; this was the reality back in
the days when a “Sawbones” surgeon’s skill was largely a function of the speed of amputation.
With the advent of modern pharmacology, surgical pain could in theory be eliminated (Langford,
2006). Despite this, too often perioperative pain tenaciously persists (Brennan et al., 2007).
Classification of pain.
Pain may be classified based upon the mechanism of its generation or the duration of
painful sensation. The primary mechanisms of pain are nociceptive and neuropathic; the
duration of pain is traditionally considered as acute (less than 3-6 months) or chronic (more)
(Turk & Okifuji, 2010).
Nociceptive pain is usually associated with a distinct cause. In the surgical setting it is
caused by the trauma of surgery and related disease. The nociceptive fibers of the peripheral
nervous system respond to damage and transmit signals interpreted as pain. Nociceptive pain is
further subdivided into somatic and visceral pain. Somatic or body pain is usually sharp and
localized; visceral pain occurs deeper in the body and is often dull and diffuse as reviewed by
(Farquhar-Smith, 2007).
Furthermore, Farquhar-Smith (2007) described another mechanism of pain is neuropathic
pain. This type of pain is generally not associated with external stimuli, caused instead by
malfunctioning pain neurons. It may be considered a dysfunction of the pain pathways, serving
no purpose for the sufferer. Examples are diabetic neuropathy, cancer pain, or pain occurring
after a stroke.
Acute pain generally has a specific cause; chronic pain may continue long after the
primary disease mechanism is resolved or may be due to the continuing progression of the
disease. As a disease progresses (e.g., a cancer metastasizes), pain and the need for relief may
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increase, usually requiring larger opioid doses. “Progressive and prolonged stimulation of pain
causes increased excitation of neurons in the dorsal horn of the spinal cord. This phenomenon is
sometimes referred to as ‘wind-up pain’” (Katz, 2002, p. 67).
Pain of any classification is a matter of degree; yet as a subjective phenomenon, it is
difficult to quantify precisely. Unfortunately, “[t]he lack of quantifiable measures of pain
character and intensity as well as relief negatively affects practice and research” (O'Malley,
2005, p. 236). Despite this, the CRNA needs to be able to estimate the patient’s pain in order to
control it. Various pain scales are used in the clinical setting with simplistic but helpful icons
such as smiling or frowning faces. These help the patient report the degree of pain and the
clinician to titrate the analgesic dose to achieve optimal pain management.
Pharmacology for pain.
The modern array of drugs available to treat pain is effective and quite safe when handled
with proper care and expertise. Opioids are very effective analgesics, making them the mainstay
in managing pain. Newer opioids (e.g., fentanyl and hydromorphone) have further improved
pain management (Inturrisi, 2002). Some of the major concerns with opioid treatment include
tolerance, addiction, and dependence. Since opioids act by binding to opioid receptors, some
preclinical studies have used simultaneous receptor engagement modalities in order to minimize
these (Morgan & Christie, 2011). Careful calculation of the minimum effective opioid dose is
necessary.
Optimal opioid dose calculation.
Calculating the proper dose is complex (Mehta & Langford, 2006). There is often a
maintenance component to the baseline dose which must be converted to common units and
added to the total dose. This is ideally done via an opioid calculator which converts the patient’s
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maintenance opioid dose to a morphine-equivalent and then to the opioid used perioperatively
(Pereira, Lawlor, Vigano, Dorgan, & Bruera, 2001).
Despite the precision and convenience of an opioid calculator, most practitioners simply
rely upon experience when determining doses (Plagge, Ruppen, Ott, Fabbro, Bornand, &
Deuster, 2011), which is fine in principle, but could be a source of errors. Errors are typically
corrected in subsequent doses by a feedback process (Plagge et al., 2011), continually increasing
the dose according to the patient’s pain response until (ideally minimum) sufficient dosing is
realized, or decreasing it if side effects become excessive (e.g., respiratory depression). Initial
patient pain is a byproduct of initial suboptimal dosing since the titration process takes time.
Davis, Johnson, Egan,Vezina, Snell, and Swenson (2003) presented a case report
detailing how they experimentally determined the perioperative response of an opioid tolerant
patient to fentanyl. Feedback from the patient recorded as vital signs were used to titrate the
proper dose, which was extremely high. Davis et al. (2003, p. 1662) pointed out:
Our target fentanyl effect-site concentration of 73 ng/ml was 50-70 times
larger than the concentration usually associated with analgesia in opioid
naïve patients. It is extremely unlikely that such an aggressive infusion rate
would have been attempted in the absence of information gained during her
initial response to a large-dose fentanyl infusion.
This illustrates the tremendous increase in opioids that some patients need. As Davis and
colleagues perspicaciously concluded, these patients are not likely to receive their optimal dose
without extra effort on the part of the pain team. Using an opioid calculator minimizes the need
for titration and the resulting pain and side effects; yet, even the most careful patient history and
opioid calculation may be overridden by the patient’s actual response to the planned analgesia.
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Emergence of effective opioid calculation methods to convert oral morphine to IV dose would
help alleviate these problems (Patanwala, Duby, Waters, & Erstad, 2007).
Preemptive analgesia.
The postoperative patient is extremely vulnerable and may have experienced significant
surgical trauma. Preoperative opioid dose calculations, which take into consideration
maintenance dose consumption, can help prevent post-operative pain, as can judicious use of
adjuvant medication (Katz, 2002). The effects of preoperatively administering non-opioids may
also be beneficial, sometimes reducing perioperative opioid requirements by 20-35% and
increasing the duration of pain relief (American Society of Anesthesiologists, 2004).
Multimodal analgesia.
Multimodal analgesia is the clinical practice of combining opioids with other drugs and
techniques to achieve additive or synergistic effects. Various opioids may also be used, since
each has a somewhat different pharmacological profile and attendant side effects. Additionally,
different routes may be chosen for delivery including oral, parenteral, subcutaneous, and
intravenous.
The major drug categories used in multimodal analgesia comprise local anesthetics, nonsteroidal anti-inflammatory drugs (NSAIDs), alpha2-adrenergic agonists, cyclooxygenase-2
(COX-2) inhibitors, NMDA antagonists, and opioids (Katz, 2002). This multimodal approach
demonstrably spares opioids, thereby sparing the patient the adverse effects of opioids (Barash,
Cullen, Stoelting, Calalan, & Stock, 2009; Dahl & Raeder, 2000; Kehlet & Wilmore, 2002;
Shang & Gan, 2003; Walker, Goudas, Cousins, & Carr, 2002). Unfortunately, the multimodal
approach is not a panacea because each of these drugs has its own side effect profile which limits
utility in some patients (Katz, 2002).
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Local anesthetics.
Local anesthetics work by blocking pain impulses at the site of injury or of nerve
conduction. Used extensively (but judiciously) in surgery, local anesthetics may allow both the
sparing of opioids post-surgically and superior pain relief. Long-acting versions are available for
this purpose (Shang & Gan, 2003). These drugs inhibit nociception by blocking nerve impulses
at some point (e.g., the spine or neural plexus) between the traumatized site and the brain. There
is a limit to the utility of local anesthetics as adjuvants due to side effects which include central
nervous system effects (Buckley, 2000).
Non-steroidal anti-inflammatory drugs (NSAIDs).
NSAIDs are very common adjunct medications in surgical anesthesia. They exhibit
opioid-sparing properties which can substantially reduce opioid requirements. The combination
may also achieve improved analgesic effectiveness over opioids alone. NSAIDs generally inhibit
inflammation by inhibiting the arachidonic acid pathway. This inhibits inflammation mediators
such as the prostaglandins. Of particular importance, cyclooxygenase-2 (COX-2) enzymes are
involved in the pathway (Moiniche, Kehlet, & Dahl, 2002). NSAIDs inhibit COX-2 activity thus
preventing synthesis of prostaglandins. COX-1 enzymes may also be inhibited leading to
hemodynamic and gastrointestinal effects (White 2005). The mechanism of inhibition of COX-2
varies among NSAIDs giving each of them a unique pharmacological profile. They may be of
long duration and preoperative administration can decrease postoperative pain and thus spare
opioids (Sinatra, 2002). Side effects are common, including gastrointestinal disturbances and
increased bleeding from anticoagulation effects (Souter, Fredman, & White, 1994).
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Cyclooxygenase-2 (COX-2) selective inhibitors.
Older NSAIDs inhibit both COX-1 and COX-2; selective COX-2 inhibitors such as
celecoxib are specific to the COX-2 enzyme, leading to reduced side effects such as bleeding and
gastrointestinal problems. COX-2 inhibitors may be used preemptively by preoperative
administration to help counteract postoperative pain. Opioid doses may thus be reduced while
pain relief is enhanced (Katz, 2002).
Gabapentin.
Gabapentin is an anti-epileptic drug that has proved useful as an adjunct to opioid
medication. Most researchers agree that preoperative gabapentin reduces opioid requirements; it
may also improve postoperative pain scores (Eckhardt, Ammon, Hofmann, Riebe, Gugeler, &
Mikus, 2000). Gabapentin also displays a strong anti-hyperalgesic effect, enabling the clinician
to treat hyperalgesic pain and simultaneously reduce the amount of opioids (Buvanendran &
Kroin, 2007; Buvanendran, Kroin, Della Valle, Kari, Moric, & Tuman, 2010; Mao & Chen,
2000).
Dexmedetomidine.
Dexmedetomidine is a relatively new opioid-sparing adjunct (White, 2005). It is a highly
selective centrally acting alpha2 adrenergic agonist (White, 2005). It also minimizes muscle
rigidity and respiratory depression (Arain, Ruehlow, Uhrich, & Ebert, 2004).
In a randomized, controlled, double-blind study conducted by Lin et al. (2009),
dexmedetomidine was used in combination with morphine (versus morphine alone) in 50 out of
100 patients who received PCA after undergoing total hysterectomies. These patients used 29%
less morphine even while reporting less pain, and the incidence of nausea and over-sedation was
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lower, demonstrating the opioid sparing and side-effect reducing properties of dexmedetomidine
when used in conjunction with morphine.
Ketamine.
Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist. It is commonly used
in clinical practice and in perioperative pain control (Kissin, 2005). Ketamine may be used at
sub-anesthetic doses to spare opioids and provide better analgesia (Himmelseher & Durieux,
2005; Koppert & Schmelz, 2007). Angst and Clark (2010, p. 514) noted, “A large body of work
in laboratory animals indicates that ketamine can block the development of opioid tolerance and
opioid-induced hyperalgesia and reverse both phenomena, at least partly, when already present.”
Ketamine is useful in preventing opioid-induced hyperalgesia in patients receiving chronic high
doses of opioids (Gottschalk & Smith, 2001; Kehlet & Dahl, 1993; Kissin, 2005).
Droperidol.
Droperidol may be used as an opioid adjuvant (Richards, Richards, Ozery, & Derlet,
2011). It is similar to haloperidol and does not cause respiratory depression, though it may cause
amnesia.
Barriers to optimal pain management.
There exist many potential barriers to optimal clinical practice (Glajchen, 2001).
Removal of these barriers may be effected by system changes, educational advancement, and
personal growth, as well as attitude changes (Gunnarsdottir, Donovan & Ward, 2003).
For the purpose of this study, “barriers” are any personal or system problems that cause
suboptimal treatment of the opioid tolerant patient. Barriers for pain management of patients
generally may include ignorance, fear, negative attitudes, communication problems, a rushed
workplace, legal concerns, cultural bias, fear of addiction or respiratory depression, patient fears,
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lack of calculation skills or assessment ability, among others (Murnion, Gnjidic, & Hilmer,
2010).
A nursing study shed light on this as well. Bourne (2008) studied the current practice in
London hospitals of opioid tolerant pain management. Her results revealed that none of the 10
hospitals had a protocol in place for cancer patients who are opioid dependent even though 9 out
of 10 have a regular practice including opioid tolerant patients. Similarly, none of the hospitals
used the same method of PCA for patients who were on opioids preoperatively. Thus, high
variability was observed among hospitals when treating pain in opioid tolerant patients.
Management of perioperative pain in the patient with prior use of opioids requires a deeper
understanding of the patient and their pain experience, and it is essential to think in advance
about the patient’s post-operative response to acute and chronic pain. The demonstrated lack of
consistency does not prove a problem—ideally, it could be the result simply of individualizing
care appropriately—but it does raise questions as to whether there should be more of a “best
practices” approach via improved guidelines, and whether effort is needed to make the opioid
tolerant pain care less an art and more a science (Bourne, 2008).
Medical legal scrutiny.
Legal and other system barriers may contribute significantly to the under-treatment of
pain. O’Malley (2005) made the point that “[a]nother hidden force supporting the under
treatment of pain are [sic] the fears of regulatory scrutiny in prescribing opioids, which translates
into tolerance for poor care” (p. 236). Opioids generally are controlled substances in the US (and
most countries) where there are six schedules of ever-greater control depending upon their abuse
potential and medical utility (Dews & Mekhail, 2004). Federal laws are designed to prevent
abuse and diversion of drugs while permitting legitimate medical use (Gilson & Joranson, 2002).
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State regulations, which may be more restrictive than federal laws, often play a major role in
controlling the medical practices of clinicians. That it is safer from a legal perspective to underprescribe opioids may effect a non-medical administrative or psychological barrier to optimal
pain relief (Gilson & Joranson, 2002), leading to poor pain management in some patients
(O'Malley, 2005).
Summary
This section discussed the theoretical framework behind this study by describing
Benner’s theory of novice to expert practice and identifying barriers to pain management and the
importance of removing such barriers for effective pain management, particularly from an expert
CRNA practice perspective. The review of literature identified aspects of pain including its
classification, mediators, mechanisms of origin, analgesics, and the resistance mechanisms to
effective opioid treatment, such as hyperalgesia and tolerance. Finally, emphasis was also placed
on the need for developing optimal opioid dose calculations, the role of preemptive analgesia and
multimodal analgesia, and the use of adjuvants during pain management. The literature on
barriers to optimal treatment of opioid tolerant patients was also reviewed. The methodology of
the study will follow in Chapter 3.
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Chapter 3: Methodology
The purpose of this study is to gain and promulgate insights into barriers in optimal
CRNA pain management of opioid tolerant patients so as to help remove such barriers, via
surveying CRNAs regarding their self-perceptions of the matter. This chapter addresses the
research design, instrumentation, sampling, ethics, and data collection as they are relevant to this
project.
Research Design
The study uses a descriptive online survey that was distributed to a random sample of
CRNAs provided by the American Association of Nurse Anesthetist (AANA). Subjects were
allowed a fourteen day period to complete the survey, and were advised that completion would
take less than three minutes. All respondents completed a multiple-choice questionnaire
assessing their self-perceptions of management of opioid-tolerant patients, e.g., their attitudes
towards current modalities and protocols for dealing with these, and the barriers commonly
encountered when caring for this population (See Appendix A).
Methodological Rationale
The goals of a descriptive study are to observe, describe, and document aspects of a
reality in situ, as it occurs naturally (Polit & Beck, 2011). A questionnaire was created for this
study as it represents a standardized, cost-effective, and anonymous instrument that is capable of
reaching a large and geographically dispersed sample (Frazer & Lawley, 2000; Polit & Beck,
2011). The questionnaire was structured in accord with professional relevance so that the most
useful questions were placed at the beginning, the most sensitive and emotionally charged in the
middle, and those pertaining to demographics at the end (Frazer & Lawley, 2000).
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Ethics and Protection of the Human Rights of Participants
Prior to the study’s initiation, approval was obtained from the Institutional Review Board
of St. Catherine University. In keeping with the board’s requirements, each potential respondent
was provided with an invitation informing them that participation in the study was completely
voluntary and that there was no practical risk in participating (See Appendix B). Respondents
were assured that all results would be handled anonymously, that no personal identifiers could be
connected to completed surveys, and that the choice to respond to the invitation and participate
in the survey confirmed informed consent.
Sample
The sample used for this study was drawn from the AANA’s 2010 registry of CRNAs.
The AANA was selected as a source because the vast majority of all CRNAs in the United States
are members of the organization and practice in many setting including urban,
university/teaching and rural hospitals. The source population included all such currentlypracticing CRNAs who have either been certified or re-certified. More than 29,000 AANA
members met the selection criteria, and 2,500 were randomly selected for participation in the
study. These 2,500 were e-mailed an invitation to participate, an explanation of the survey, and a
link to the survey itself. The response rate on individual questions ranged from 25.6% (640
respondents) to 28.9% (717), the response rate generally declining marginally with each
question.
Data Collection
Data for this study were collected using a controlled-access web-based multiple choice
questionnaire designed by the investigator in consultation with three Masters-certified CRNA
educators and one board-certified anesthesiologist, all specializing in pain management and
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research, and a professional survey analyst. The instrument was first tested using a small pilot
study of ten randomly selected CRNAs so as to confirm the questions’ validity. Thus this
questionnaire was sent to 10 randomly practicing CRNAs across the United States. The feedback
from these CRNAs includes: ease of understanding the material, relevance of the material to
their practice, clarity of the material, and the time consumed to finish the questionnaire. It made
use of the Likert frequency scale, which is regularly used in research to measure attitudes or
opinions because its ordinal nature allows respondents to express a full range of views in their
responses (Matutina, Newman, & Jenkins, 2010; Polit & Beck, 2011).
Aside from asking basic demographic questions, the survey consists of three overarching
groups of questions: eight questions regarding self-perceptions (e.g., attitudes towards opioidtolerant patients, assessment practices, and knowledge of pain modalities); two questions related
to education and CEUs; and four questions regarding extant barriers inhibiting provision of
optimal pain relief (See Appendix A). All of the questions were in line with the research
question and focused on analgesia for the opioid-tolerant patient population.
Data Analysis
All data obtained were analyzed through standard methods for each of the survey’s
questions. This analysis provided the foundation for the study’s insights regarding pain
management practices for CRNAs dealing with opioid-tolerant populations. Findings are
presented in Chapter 4.
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Chapter 4: Results
CRNAs along with anesthesiologists are entrusted with the duty of alleviating pain.
Adding complexity to an already complicated process is opioid tolerance. This study was
designed to identify and understand barriers that potentially impede delivery of adequate pain
management to opioid tolerant patients. As the primary instrument of the study, a questionnaire
was designed and submitted to 2500 CRNAs throughout the United States, whose names are in
the AANA database; of those surveyed, 28.9% (717) responded, a minimum of 25.6% (640) on
each question. Missing or invalid responses were omitted from particular results, the n value on
each survey question’s chart showing the quantity of respondents to that question.
Demographics
Educationally (Figure 4), over three-fourths (78.5%) of the participants have a master’s
of nurse anesthesia equivalent or higher degree, 89.3% are working full time (Figure 5), and
92.9% work in hospitals (Figure 6). The clinical practice settings of participants (Figure 7) were
as follows: in rural/small town (27.1%), university/teaching (33.6%), suburban (27.9%), or
urban/community (11.5%). The median age (Figure 8) was 50 years (IQR=16, range 29 to 78
years), with a mean years of CRNA experience of 16.0 years (SD+/-10.9, range 1.5 to 55 years)
(Figure 9).
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What is Your Highest Level of Education as a CRNA?
n = 646

2.6% (17)

Doctorate

75.9%
(490)

Masters in Nursing Anesthesia

9.1% (59)

Bachelors of Science

12.4% (80)

Certificate
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Figure 4. Survey question: what is your highest level of education as a CRNA?

What is Your Current Employment Status?
n = 646

10.7% (69)

Part time

89.3%
(577)

Full time
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Figure 5.. Survey question: what is your current employment status?
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What Best Describes Your Practice?
n = 646
Self-employed/contract

1.7% (11)

Free-standing ambulatory center

1.2% (8)
2.9% (19)

Anesthesiologist-owned

1.2% (8)

CRNA-owned

92.9%

Hospital Employee
0
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400

(600)
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Figure 6.. Survey Question: what best describes your practice?

Which Best Describes Your Clinical Setting?
n = 646

Rural/Small Town

27.1% (175)

Suburban/Community

27.9% (180)
33.6%
(217)

University/Teaching Hospital
11.5% (74)

Urban
0

50

100

150

Number of CRNAs

Figure 7.. Survey question: which best describes your clinical setting
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What is your age?
n = 641

0% (3)

70's

11.7% (75)

Age Bracket

60's

38.5%
(247)

50's
26.4% (169)

40's

22.5% (144)
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0% (3)
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Figure 8. Survey question: whatt is your age?

Number of Years of Practice
n = 645
2.3% (15)

41 and more

5.2% (34)

36--40

9.8% (63)

31--35

10.2% ( 66)

26--30

9.5% (63)

21--25

14.0% (90)

16--20

14.6% (94)

11--15
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Figure 9.. Survey question: how many years have you been in practice?
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The following provides a descriptive analysis of various factors that contribute directly
during the delivery of appropriate pain managemen
managementt therapy to opioid tolerant patients.
CRNA Assessment and Frequency of Opioid Tolerant Patients
Not surprisingly, almost all of the CRNAs provide personal opioid use or tolerance
assessment of patients (91.3%); it may be a concern that some report they do not (8.7%) (Figure
10). As depicted in Figure 11, 66.0% (426) of CRNAs reported that up to 20% of their patients
to be opioid tolerant, while 22.6% (146) report 21 to 40%
40%; less than 3%
% of CRNAs report in the
range of 61-100%.
100%. Taken together, all but 4 (<1%) of the CRNA participants in this study have
conducted pain management of patients who are opioid tolerant.
Do You Personally Assess Your Patients for Their History of Opioid Use or
Tolerance?
n = 704

8.7% (61)

No

91.3% (643)

Yes
0
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200

300

400
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Figure 10.. Survey question: do you personally asses your patients for their hist
history
ory of opioid use or
tolerance?
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About what Percentage of Your Patients are Opioid Tolerant?
n = 645

0.4% (3)

81-100%

2.3% (15)

61-80%

8.5% (55)

41-60%
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Figure 11.. Survey question: about what percentage of your patients are opioid tolerant?

Nature of CRNA Practice
While managing pain in opioid tolerant patients, it is beneficial that the place of
employment has the infrastructure to support acute pain management follow
follow-up,
up, yet 47% of
CRNAs involved in this study report (Figure 12)) they do not have access to acute pain
management services at their place of employment; 11% are unsure. Half of the CRNA
participants in this study work collaboratively with physicians (Figure 13);
); the balance work
independently. Among the CRNAs who have a collaborative practice (327), three-fifths
three
are
equipped with the power of making
ing routine decisions regarding pain management drug choice
and dosing, while another 16% are authorized to make all such decisions (Figure
Figure 14).
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Does Your Primary Place of Employment have Inpatient Acute Pain
Services to Follow up on Pain Management of Opioid Tolerant Patients
n = 654

11.2% (73)

Don't Know

46.8% (306)

No

42.0% (275)
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Figure 12.. Survey question: does your primary place of employment have inpatient acute pain
management services to follow-up
up on pain management of opioid tolerant patients?

Do You have a Collaborative Practice in Pain Management with an
Anesthesiologist?
n = 654

No

49.1%
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50.9%
(333)
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Figure 13. Survey question: do you have a collaborative practice in pain management with an
anesthesiologist?
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If you Work in A Collaborative Practice in Your Primary Place of
Employment, Are you The One to Make Decisions As to The Dosing and
Choice of Opioids
n = 333
0.6% (2)

No Response

1.8% (6)

Never

6.3% (21)

Rarely

15.6% (52)

Occassionally

59.5%
(198)
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16.2% (54)

Always
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Figure 14.. Survey question: if you work in a collaborative practice in your primary place of employment,
are you the one to make decisions as to the dosing and choice of opioids?

Pain Management Practices
ractices of CRNAs for Opioid tolerant Patients
Proper dosing is essential for adequate pain management. In this regard (Figure
Figure 15), 6%
of respondents were always and 71% usually confident in their dosing of opioid tolerant patients.
It is a matter of concern that 17% of CRNAs expressed only occasional confidence, 5% had
confidence only rarely, and under 1% none at all, though it could be that in those cases doses are
set by another anesthesia provider, possibly rendering the lack of confidence in
inconsequential.
consequential.
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Do You Feel Confident in Determining Proper Doses for Opioid Tolerant
Patients
n = 666
0.6% (4)

Never

6.0% (40)

Rarely

16.8% (112)

Occassionally

71.8%
(478)

Usually
4.8% (32)

Always
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Figure 15.. Survey question: do you feel confident in determinin
determining
g proper doses for opioid tolerant
patients?

An opioid calculator assists the CRNA in determining baseline opioid doses.
doses The vast
majority of the CRNAss in this study (71%) never use an opioid calculator and only 1% always
do (Figure 16). Four-fifths
fifths (79%
(79%—53% of CRNAs usually, 26% always)) do alter their pain
management modalities for opioid tolerant patients ((Figure 17).
). Respondents reported use of
adjuvant medications with opioid tolerant patients an average of 68% of the time (Figure
(
18),
and 91% of CRNAs employ multi
multi-modal
modal therapy including regional or local anesthesia with
such patients (Figure 19).
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For your Opioid Tolerant Patients, is an Opioid Calculator Used to
Determine the Baseline Dose
n = 666
71.0%
(473)

Never
17.0% (113)
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Figure 16.. Survey question: for your opioid tolerant patients, is an opioid calculator used to determine the
baseline dose?

How Often Do You Alter Your Pain Management Modalities for Your
Patients with a History of Opioid Tolerance
n = 666
1.1% (7)

Never

3.3% (22)

Rarely

17.1% (114)
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26.6% (177)
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Figure 17.. Survey question: how often do you alter your pain management modalities for your patients
with a history of opioid tolerance?
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In Approximately What Percentage (0
(0-100)
100) of Opioid Tolerant Cases Do You Include Adjuvant Pain
Medication?
n = 660

22.1%
(147)

100
17.1% (113)
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11.4% (75)
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3.2% (21)
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Figure 18.. Survey question: in approximately what percentage (0
(0-100) of opioid tolerant cases do you
include adjuvant pain medication?

How often for Opioid Tolerant Patients Do Use Multimodal Pain Regimens
That Include Local or Regional Anesthesia?
n = 666
1.2% (8)
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Figure 19.. Survey question: how often for opioid tolerant patients do you use multimodal pain regimens
that include local or regional anesthesia?
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Barriers to Adequate Pain Management in Opioid Tolerant Patients
A disadvantage in using opioids outside a hospital context is the risk of addiction; only
3.9% of CRNAs agree (3.3% agree, 0.6% strongly agree) that this is a barrier to optimal pain
management for in-hospital, perioperative use (Figure 20).
Fear of Making the Patient Addicted to Opioids
n = 657
0.6% (4)

Strongly Agree

3.3% (22)

Agree

14.6% (96)

Neither Agree or Disagree

41.7%
(274)

Disagree

39.7% (261)

Strongly Disagree
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Figure 20.. Survey question: in your practice, is the fear of making patients (more) addicted to opioids a
barrier to optimal pain management for opioid tolerant patients?
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In this study, 30.0% of CRNAs reported fear of induction of respiratory depression as a barrier to
optimal pain management, while 18
18.6% were neutral and 51.3% disagreed (Figure
Figure 21).
Fear of Respiratory Depression in the Opioid Tolerant Patient
n = 657
3.3% (22)

Strongly Agree

26.7% (176)

Agree
18.6% (122)

Neither Agree or Disagree
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Disagree
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Strongly Disagree
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Figure 21.. Survey question: in your practice, is the fear of causing respiratory depression a barrier to
optimal
imal pain management for opioid tolerant patients?

Another potential barrier might include a lack of CRNA autonomy, but only 25% of
CRNAs reported this; most CRNAs (54% overall, 19% strongly) expressly denied this as a
barrier (Figure 22).
Lack of CRNA Autonomy in Determining Perioperative Pain Management
n = 657
5.3% (35)

Strongly Agree

19.5% (128)

Agree

20.9% (137)

Neither Agree or Disagree

35.5%
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Disagree
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Figure 22.. Survey question: in your practice, is your lacking autonomy in determining perioperative pain
management
ent a barrier to optimal pain management for opioid tolerant patients?
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The
he most widely and strongly agreed upon barrier is a lack of formal, profession-wide
profession
pain management guidelines specifically dealing with opioid tolerant patients. Fifty percent
agreed
eed and 22% disagreed that envisaging specific pain guidelines would eliminate a barrier in
pain management in these patients (Figure 23).
Lack of Pain Guidelines Specifically for Opioid Tolerant Patients
n = 657
9.1% (60)

Strongly Agree

40.9%
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27.4% (180)
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Figure 23.. Survey question: in your practice, is a lack of certified, professional guidelines specifically for
opioid tolerant patients a barrier to their optimal pain management?

Nearly
early all CRNAs (90%) do not consider fear of litigation as a barrier during the pain
management process (26% neither agree nor disagree, 46% disagree, 18% strongly disagree);
only 1% strongly agree that it is ((Figure 24).
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Fear of Litigation Related to Poor Pain Relief in Opioid Tolerant Patients
n = 657
1.4% (9)
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Figure 24.. Survey question: in your practice, is fear of litigation related to poor pain relief in opioid
tolerant patients a barrier to their optimal pain management?

Are There Any Other Barriers You Encounter in Managing the Pain of
Opioid Tolerant Patients?
n = 657
75.6%
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(160)

Yes
0

100

200

300

400

500

Number of CRNAs

Figure 25.. Survey question: are there any other barriers you encounter in managing the pain of opioid
tolerant patients?

In one open-ended
ended question, respondents were asked to identify other barriers that
impede practice Figure 25). Three
Three-fourths
fourths of the respondents (75.6%) either explicitly or
implicitly indicated there were no other significant barriers. However, one
one-quarter
quarter (24.4%) of
respondents did offer
fer a positive response
response—Table 1 consists of a summary table of the more
frequent answers.
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Table 1. Additional barriers
Staff Issues

23

Patient Prevarication

11

Bleeding Increase

11

Lack of guidelines

10

Lack of knowledge

7

Problems with multimodal

7

Rushed work conditions

6

Table 1 categorically summarizes most of (75) the 138 typed responses. Responses not
summarized here included more idiosyncratic (e.g., hospital-specific) or broad (e.g., “too many”)
concerns and did not seem to be part of broader patterns. Written responses related to barriers to
practice were analyzed and categorized to determine that the largest groups of write-ins were:
staff cooperation issues (23), patient prevarication (11), bleeding increases (11), lack of
guidelines (10) (even though this was a specific question earlier in the survey), lack of
knowledge (7), problems with multimodal anesthesia (7), and rushed work conditions (6).
Continuing education provides an opportunity to accommodate recent advancements in
drug discovery and therapy. Almost 4/5 of the CRNA participants (78%) in this study had
Continuing Education Units (CEUs) related to care of patients who are opioid tolerant within the
past 2 years (Figure 26), and yet a striking 94% of the participants acknowledged the importance
of having additional CEUs pertaining to opioid tolerant pain management (Figure 27).
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Have you had any continuing education units (CEUs) related to pain
management for opioid tolerant patients?
(n = 646)
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Figure 26.. Survey question: have you had any CEUs related to pain management for opioid tolerant
patients?

How Important to You Personally Would Additional CEUs be Regarding
Pain Management of Opioid Tolerant Patients?
n = 650
5.7% (37)
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Figure 27.. Survey question: how important to you personally would additional CEUs be regarding pain
management of opioid tolerant patients?

In summary, there is a need for professional guidelines for managing pain of opioid
tolerant patients, and education toward that end.
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Chapter 5: Discussion
The main objective of this study was to identify CRNA self-perceptions of pain
management barriers when caring for opioid tolerant patients, and provide essential information
to guide mitigating or eliminating those barriers, thereby reducing pain in this vulnerable
population. This is believed to be the first CRNA-oriented study of this kind.
All CRNAs have a great responsibility to the patient because they are usually the in-room
providers of pain relief in the intraoperative setting; this is magnified since nearly all but the
most junior CRNAs should be experts in Benner’s use of the term (due not only to their
advanced academic and clinical training but also, and in some ways even more importantly, to
the certification’s requirements of prior nursing experience, implying that a “beginning” CRNA
is already a proficient or expert nurse), and that expertise entails both greater authority and
greater responsibility. It follows that the training, attitudes, beliefs, and concerns of the CRNA
will directly influence the care experienced by the patient, and that the self-perceptions of
CRNAs provide insight into perioperative pain management and the associated barriers.
This systems change project, then, taps the deep knowledge and wisdom of hundreds of
practicing CRNAs representing a remarkable amount of clinical experience and insight.
Referring to expert practitioners, Benner (1984) puts it well: “Their rich backlog of experience
enables expert clinicians to create order in the midst of chaos” (p. 116).
Findings
CRNAs are registered nurses who possess at least a baccalaureate degree and one year of
clinical experience prior to entering CRNA education; the majority of the participants in this
study have earned a master’s degree. The American Association of Colleges of Nursing (AACN,
2006) recommends requiring a doctorate for entry to practice for all advanced practice nursing

Running head: OPIOID TOLERANT

50

graduate programs by 2015; the AANA (2007) recommended mandating the DNP degree by
2025. Only 2.6% of the random sampling in this study had such a degree, but if these mandates
become a requirement for certification, the percentage will increase dramatically in coming
years.
Successful perioperative pain management inevitably involves teamwork. Most CRNAs
execute their function under supervision (Jones & Fitspatrick, 2009) and collaborate with
physicians, with the nature of this collaboration playing a critical role in the quality of care
provided to patients (Taylor, 2009). However, among the participants in this study, 49.1% do
not have such a collaborative arrangement, implying that such CRNAs work alone and are
therefore more autonomous. It should also be noted that the majority of the collaborating
CRNAs usually or always have freedom to choose the types and dosages of the analgesics that
are to be administered to patients. A recent report (Jordan, 2011) provided arguments that the
removal of excess supervision is vital to ensure optimum patient access to care—this topic needs
further systematic study. This autonomy may be justified if the CRNA has climbed the expertise
ladder as described by Benner (1984). Among surveyed CRNAs generally, a quarter agree
(5.3% strongly, 24.8% overall) that lack of CRNA autonomy in determining perioperative pain
management is a significant barrier —whether this issue is a glass ¼ full or ¾ empty (20.9%
neutral, 54.5% disagreeing) is difficult to discern, warranting further research.
The pain management team ideally includes acute pain services. Of CRNAs surveyed,
42.0% reported having such services, 46.8% report lacking such services, and a disturbing 11.2%
report that they do not know whether they have such services available or not. The lack of
awareness of available resources could in itself create a barrier to optimal pain management.
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Another putative barrier is the fear of inducing respiratory depression when administering
opioids, seen by a significant but not overwhelming 30% of study participants as an actual
barrier. Respiratory depression is indeed a real risk, but opioid tolerant patients can receive far
greater analgesic dosing before this becomes a problem (Thompson & Ray, 2003).
Two other possible barriers to optimal pain management for opioid tolerant patients
reassuringly proved to be statistically minor issues. Fear of making the patient addicted (3.9%
agree overall, 0.6% strongly; 96.1% neutral or disagreeing) is not a serious barrier in the view of
CRNAs. Addiction has proven to be a non-issue when using opioids precisely to manage pain
(Compton & Athanasos, 2003), even over long periods, let alone perioperatively; so while the
survey results are low, the evidence suggests they would ideally be zero. Fear of pain-reliefrelated litigation (10.5% agree overall, 1.4% strongly) is higher, but also quite rare, especially
given medicine- and society-wide concerns about excessive litigation.
The preceding important points being noted, by far the most dramatic results of this
survey demonstrate the need and desire for additional precise CRNA guidance specifically
concerning management of opioid tolerant patients. The greatest barrier to optimal care reported
in this study is an insufficiently detailed knowledge of just what care is needed. Three elements
establish this finding.
Opioid calculator.
First is the lack of use of an opioid calculator to determine precise morphine equivalents
for opioid tolerant patients: 71.0% never and another 17.0% only rarely use an opioid calculator;
just a miniscule 1.1% always do. Individualizing pain management is generally critically
important (Stomberg, Sjostrom & Haljamae, 2003), and particularly so for opioid tolerant
patients. Using intuition or experience to estimate a baseline is much better than ignoring opioid
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tolerance altogether, but may not be enough, particularly when simple and reliable opioid
calculators are available (Agency Medical Directors’ Group, 2010). Opioid calculators convert
pre-operative oral opioid dosages into their IV morphine equivalents and back again (Patanwala,
et al. 2007). Excessive quantities of opioids can lead to respiratory depression, and inadequate
levels do not alleviate pain.
Professional guidelines.
Second, one explicit barrier survey question had dramatically more agreement (50.0%)
than disagreement (22.5% overall, 6.1% strongly) or neutrality (27.4%): the lack of formal
professional guidelines for pain management of opioid tolerant patients. Compared to survey
results for other barriers noted above, this is decisive. This fits well, too, with the impressions
gained from studies such as Bourne’s (2008) in which inconsistency of treatments and protocols
for opioid tolerant patients was suggestive of inadequate guidance more than rigorous, patientcentric treatment individuation. Understanding the use opioids for treatment of chronic noncancerous pain (e.g., as reviewed by Ballantyne & Mao, 2003) could assist efforts to find proper
perioperative procedures and dosing.
Additional, targeted CEUs.
Third, an exceptional 94% of participants believed they would benefit from more CEUs
regarding handling opioid tolerant patients. Interestingly, this 94% includes even the vast
majority of those who did not agree that the lack of guidelines was a true barrier to optimal
care—even without guidelines, additional education would be beneficial. This is underscored by
a recent study conducted by Leegaard, Watt-Watson, McGillion, Costello, Elgie-Watson, and
Partridge (2011), which identified the need for nurse education as a key determinant toward
achieving effective pain management in patients before and after surgery. Some modes of

Running head: OPIOID TOLERANT

53

education might include webinars or Internet AANA modules as well as the more traditional
“brief in-services, hands-on learning, lunch-and-learn sessions, and designated education days”
(pp. 318-319).
Together, these findings suggest that targeted, evidence-based, precise guidance
(ensuring use of an opioid calculator, creating professional guidelines, and additional CEUs)
offers the best hope for improving pain relief for opioid tolerant patients. Creating such state-ofthe-art guidance for managing these patients is a very challenging task, but this survey evidence
indicates that it is the most important means to the end of better relieving their pain.

Future Studies.
Future research could use a numerical scale instead of a Likert scale when querying
CRNAs about percentages of their anesthesia patients who are opioid tolerant. Given the heavy
preponderance of CRNAs who reported “1 to 20%” as their range (66%), a finer-grained
breakdown would have been more appropriate. Additionally, the issue of CRNA confidence
relating to proper dosing of opioid tolerant patients may warrant additional investigation. It is
very important to consider also that higher confidence is not necessarily an indication of higher
competence: in a situation where the CRNA has explicitly incomplete knowledge (e.g., about a
patient’s opioid history), a more-expert CRNA may have less confidence in the precise dosing.
Benner’s (1984) framework also offers opportunities for future research along these
lines. While unfortunately this study did not include the requisite background on pre-CRNA
nursing experience, which would combine with years of experience as a CRNA to offer an
overall time frame for statistically estimating a level of expertise, this lack does offer one clear
path for additional questions and analyses. Such research may require deriving a mathematical
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model from Benner's more intuitive philosophy, which derivation may be challenging but could
offer informative correlation data allowing particular instantiations of Benner's philosophy to be
tested.
Benner, Expertise, and the DNP degree.
Future research notwithstanding, looking at how these actual data fit with Benner’s
theoretical framework is both illuminating and complicated. As noted earlier, upon entering
practice, most CRNAs by virtue of their education (both the criteria for admittance and the actual
education itself) and experience (not only as CRNAs, but as nurses before their anesthesia
training) may already be experts in Benner’s sense, but at the same time lack the most up-to-date
expertise in managing the pain of opioid tolerant patients. Core components of nurse anesthesia
are fairly static and subject to accumulated individual experience, such as the basic science and
the all-important human components; other aspects are subject to rapid change, such as the latest
anesthesia empirical evaluations and technological breakthroughs. Sound original training and
years of experience suffice for the former, but not for the latter. Use of the opioid calculator, the
creation of new guidelines, and the acquisition of additional, targeted CEUs are all important
supplements for core nursing and nurse anesthesia expertise. Indeed, one way of understanding
this systems change project is to see it entirely as a tool to ensure that CRNAs’ expertise, in
Benner’s sense, includes the best practices for opioid tolerant patients.
The DNP degree specifically facilitates the kind of expertise required to effect systems
change. The AACN (2006) determined eight essential characteristics of doctoral degree
programs for Advanced Practice Registered Nurses (APRNs) to imbue DNPs with the
capabilities to lead such change. The IOM (2010) report on the future of nursing dovetails with
this, encouraging registered nurses (RNs) and APRNs to pursue lifelong learning to maximize
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their professional training and thereby optimize healthcare outcomes for their patients, noting
that getting the most from nurses involves letting them “practice in accordance with their
professional training” (p. xii). With its emphasis on healthcare policy, leadership, collaboration,
and systems theory, the DNP degree takes this training and expertise beyond the individual level
to the systems level, so as to benefit not just the individual patients, but the system that must care
for them.
The Urgency of System Change
It’s not only important to note what the single best change from the status quo is, it’s also
critically important to understand its urgency, for intermingled moral and economic reasons.
When postoperative pain is inadequately treated, it intensifies patient physiological responses,
which may in turn lead to serious complications.
And as is genuinely self-evident but so often neglected (if impossible to truly forget),
needless pain needs to be stopped simply because it is needless pain, even if there were no other
health or economic benefits. When improperly managed, perioperative pain can easily become
severe; pain can render one’s life truly miserable, to the point even of making death emotionally
preferable to life. Unrelieved pain is not simply a private tragedy—it is socially unjust and
professionally unethical.
CRNAs equipped with the DNP have both the nursing experience and systems change
theory, informed by social justice and leading nursing and leadership thought, to successfully
systemically champion the needs of those individuals and groups who are currently
marginalized—most particularly, the opioid tolerant patient—resulting not just in ad hoc
improvements, but improvements that persist and pervade the entire organization.
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This study adds to the body of literature concerning CRNA pain management knowledge
and practice patterns related to opioid tolerant patients, providing baseline evidence of CRNA
self-perceptions of pain management practices and raising awareness in the professional body
that will lead to systems change in the form of educational development and professional
guidelines, improving the subjective experience and measurable outcomes when perioperatively
managing the pain of such vulnerable patients.
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Appendix A: CRNA Pain-Management Survey Questionnaire
1. Are you currently practicing as a CRNA?
a. Yes (continue with survey)
b. No (exit survey)
2. Do you personally assess your patients for their history of opioid use or tolerance?
a. Yes
b. No
3. About what percentage (0-100) of your patients are opioid tolerant? ___

If the above percentage > 1%, then answer the following 3 questions:
4. How often do you alter your pain management modalities for your patients with a history
of opioid tolerance?
a. Always
b. Often
c. Occasionally
d. Rarely
e. Never
5. When dealing with patients with a history of opioid usage, do you make calculations to
convert oral opioid dosages to IV dosages?
a. Always
b. Often
c. Occasionally
d. Rarely
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e. Never
6. In approximately what percentage (0-100) of opioid tolerant cases do you include adjunct
pain medications during your intraoperative pain management? ___
7. How often do you include multimodal pain regimens for these patients?
a. Always
b. Often
c. Occasionally
d. Rarely
e. Never
8. Does your institution/primary place of employment have inpatient acute pain services to
follow up on pain management of opioid tolerant patients?
a. Yes
b. No
c. Don’t know
9. Do you have a collaborative practice in pain management with an anesthesiologist?
a. Yes
b. No
10. If you work in a collaborative practice in your primary place of employment, are you the
one to make decision as to the dosing and choice of narcotics?
a. Always
b. Often
c. Occasionally
d. Rarely
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e. Never
f. I do not work in a collaborative practice.
11. Have you had any continuing education units (CEUs) related to pain management for
opioid tolerant patients?
a. Never
b. Yes, within the last 2 years
c. Yes, more than 2 years ago
12. Would you personally benefit from more CEUs regarding management of opioid tolerant
patients?
a. Yes
b. No

The following questions refer to the barriers to providing optimum pain relief for opioid
tolerant patients. For each of the following four items, do you agree or disagree that in your own
practice it is a barrier to optimal pain management with respect to opioid tolerant patients?

1. Fear of addiction
a. Strongly disagree
b. Disagree
c. Neither agree or disagree
d. Agree
e. Strongly agree
2. Respiratory depression
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a. Strongly disagree
b. Disagree
c. Neither agree or disagree
d. Agree
e. Strongly agree
3. Lack of CRNA autonomy
a. Strongly disagree
b. Disagree
c. Neither agree or disagree
d. Agree
e. Strongly agree
4. Lack of specific pain guidelines for opioid tolerant patients
a. Strongly disagree
b. Disagree
c. Neither agree or disagree
d. Agree
e. Strongly agree
5. Are there any other barriers you encounter in managing the pain of opioid tolerant
patients?
a. Yes
i. Please describe any other barriers: _____________________
b. No
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Demographic Questions
1. What is your age? ____________________
2. What is your highest level of education as a CRNA?
a. Certificate
b. Bachelors of Science
c. Masters in Nursing Anesthesia
d. Doctorate
3. How many years have you practiced as a CRNA? ___________________
4. What is your current employment status?
a. Full time
b. Part time
5. Which best describes your practice?
a. Hospital
b. CRNA-owned
c. Anesthesiologist-owned
d. Self-employed/contract
6. Which best describes your clinical setting?
a. Rural/small town
b. University-based
c. Suburban/community
d. Urban
e. Free-standing ambulatory center
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Appendix B: Survey Informed Consent
Rebecca King MNA-CRNA, DNP-student invites you to participate in this research
study.
Title: OPIOID TOLERANCE: SELF-PERCEPTION OF PAIN MANAGEMENT OF
THE OPIOID TOLERANT PATIENT--A SURVEY OF CERTIFIED REGISTERED NURSE
ANESTHETISTS
The purpose of this study is to investigate and analyze Certified Registered Nurses
Anesthetist (CRNA) self-perceived pain management of the opioid tolerant patient. To
accomplish this, the researcher will use a quantitative design. The survey will evaluate the
participants’ perceptions of pain management of opioid tolerant patients via survey questions
with Likert scale responses. This will illuminate our understanding of CRNA care for this
clinically challenging patient group.
Your participation in this study should take less than 10 minutes. Completing this survey,
constitutes your informed consent to participate in the study. The surveys will be kept
anonymous. All results will be reported in aggregate rather than individual form. The compiled
results of the study may be published in scientific research journals or presented at professional
conferences but will not contain individually identifiable information.
The risks to you as a participant are minimal. Your participation in the study is voluntary
and will in no way affect your status as a Certified Registered Nurse Anesthetist (CRNA) or
membership with the AANA. The AANA will not provide your name or E-mail address to the
primary investigator. The loss-of-anonymity risk will be minimized by not collecting identifiers.
The results of the survey will be provided to the principle investigator in an Excel file and will
not be correlated to identify you.
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There are no known benefits to you of participation in this study. Your participation may
benefit others in society and CRNA practice generally because it may illuminate the need for a
systems change in pain management of the opioid tolerant patient.
You can choose not to participate. If you decide not to participate, there will not be a
penalty or loss of any benefits to which you are otherwise entitled.
If you have any questions about this research study, you can call Rebecca King at 507287-0513 or Dr. Margaret Dexheimer Pharris at (651) 690-6572. If you have any questions
about your rights as a research participant, you can call the Institutional Review Board (IRB) at
St. Catherine University at (651) 690-6591.

